Chaban Artem, Waschulzik Birgit, Bernhardt Denise, Delbridge Claire, Schmidt-Graf Friederike, Wagner Arthur, Wiestler Benedikt, Weber Wolfgang, Yakushev Igor
Department of Nuclear Medicine, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
Institute of AI and Informatics in Medicine, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1698-1702. doi: 10.1007/s00259-024-06601-4. Epub 2024 Jan 17.
To summarize evidence on the comparative value of amino acid (AA) PET and conventional MRI for prediction of overall survival (OS) in patients with recurrent high grade glioma (rHGG) under bevacizumab therapy.
Medical databases were screened for studies with individual data on OS, follow-up MRI, and PET findings in the same patient. MRI images were assessed according to the RANO criteria. A receiver operating characteristic curve analysis was used to predict OS at 9 months.
Five studies with a total of 72 patients were included. Median OS was significantly lower in the PET-positive than in the PET-negative group. PET findings predicted OS with a pooled sensitivity and specificity of 76% and 71%, respectively. Corresponding values for MRI were 32% and 82%. Area under the curve and sensitivity were significantly higher for PET than for MRI.
For monitoring of patients with rHGG under bevacizumab therapy, AA-PET should be preferred over RANO MRI.
总结氨基酸（AA）正电子发射断层扫描（PET）与传统磁共振成像（MRI）在预测接受贝伐单抗治疗的复发性高级别胶质瘤（rHGG）患者总生存期（OS）方面的比较价值证据。
筛查医学数据库，寻找包含同一患者的OS、随访MRI及PET检查结果的个体数据的研究。根据RANO标准评估MRI图像。采用受试者工作特征曲线分析预测9个月时的OS。
纳入5项研究，共72例患者。PET阳性组的中位OS显著低于PET阴性组。PET检查结果预测OS的合并敏感度和特异度分别为76%和71%。MRI的相应值分别为32%和82%。PET的曲线下面积和敏感度显著高于MRI。
对于监测接受贝伐单抗治疗的rHGG患者，AA-PET应优于RANO MRI。
